Prevention of cardiovascular disease after renal transplantation
- PMID: 22790074
- DOI: 10.1097/MOT.0b013e3283560a3b
Prevention of cardiovascular disease after renal transplantation
Abstract
Purpose of review: After renal transplantation, cardiovascular disease (CVD) is the leading cause of death with a functioning graft. Guidelines for prevention of CVD are mainly based on data from the general population. The purpose of this review is to give a practical approach on prevention of CVD in renal transplant recipients.
Recent findings: New epidemiological data have shown that in addition to traditional risk factors for CVD, other risk factors may influence cardiovascular risk in renal transplant recipients. Recently, a specific risk calculator for CVD in renal transplant recipients has been developed. Prevention of CVD in renal transplant recipients should include lifestyle modifications, such as prevention of overweight, smoking cessation and physical exercise. Optimal treatment of hypertension, lipid disturbances and posttransplant diabetes should be encouraged. Accumulating evidence indicates that declining graft function and graft loss are potentially modifiable risk factors in this population, which make strategies for preserving graft function important. This situation may include individual tailoring of immunosuppression and use of new immunosuppressive medications with a more favorable effect on cardiovascular risk factors and graft function.
Summary: To prevent CVD in renal transplant recipients, cardiovascular risk assessment should be performed regularly. Prevention should include both lifestyle modifications, optimal treatment of cardiovascular risk factors and strategies to preserve graft function.
Similar articles
-
Risk factors for and management of post-transplantation cardiovascular disease.BioDrugs. 2001;15(4):261-78. doi: 10.2165/00063030-200115040-00006. BioDrugs. 2001. PMID: 11437691 Review.
-
[Cardiovascular disease after renal transplantation].G Ital Nefrol. 2004 Jan-Feb;21 Suppl 26:S53-66. G Ital Nefrol. 2004. PMID: 15732047 Review. Italian.
-
[Metabolic disorders in renal transplant recipients].Acta Med Croatica. 2012 Jul;66(3):235-41. Acta Med Croatica. 2012. PMID: 23441539 Croatian.
-
Risk factors for cardiovascular disease in renal transplant recipients and strategies to minimize risk.Transpl Int. 2010 Dec;23(12):1191-204. doi: 10.1111/j.1432-2277.2010.01159.x. Epub 2010 Sep 7. Transpl Int. 2010. PMID: 21059108 Review.
-
[Hypertension after kidney transplantation].Lijec Vjesn. 2006 Nov-Dec;128(11-12):373-8. Lijec Vjesn. 2006. PMID: 17212200 Review. Croatian.
Cited by
-
Safety and Efficacy Endpoints for Mesenchymal Stromal Cell Therapy in Renal Transplant Recipients.J Immunol Res. 2015;2015:391797. doi: 10.1155/2015/391797. Epub 2015 Jul 15. J Immunol Res. 2015. PMID: 26258149 Free PMC article. Review.
-
Hypoadiponectinemia correlates with arterial stiffness in kidney transplantation patients.Clin Exp Nephrol. 2015 Jun;19(3):534-41. doi: 10.1007/s10157-014-1010-1. Epub 2014 Jul 19. Clin Exp Nephrol. 2015. PMID: 25037242
-
Active video gaming in patients with renal transplant: a pilot study.Transplant Res. 2014 Aug 9;3:15. doi: 10.1186/2047-1440-3-15. eCollection 2014. Transplant Res. 2014. PMID: 25114788 Free PMC article.
-
Serum Uric Acid and Renal Transplantation Outcomes: At Least 3-Year Post-transplant Retrospective Multivariate Analysis.PLoS One. 2015 Jul 24;10(7):e0133834. doi: 10.1371/journal.pone.0133834. eCollection 2015. PLoS One. 2015. PMID: 26208103 Free PMC article.
-
Belatacept in renal transplantation in comparison to tacrolimus and molecular understanding of resistance pattern: Meta-analysis and systematic review.World J Transplant. 2021 Mar 18;11(3):70-86. doi: 10.5500/wjt.v11.i3.70. World J Transplant. 2021. PMID: 33816147 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials